Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2

Authors :: Shuguang Yuan
Pei-Hui Wang
Ximing Shao
H. C. Stephen Chan
Xueying Wang
Junlin Dong
Hongpei Li
Ke Liu
Wu Su
Meiqing Li
Hongchun Li
Hongchang Li
Rongfeng Zou
Cui Wenqiang
Source :: ACS Pharmacology & Translational Science
Publication Year :: 2020
Publisher :: American Chemical Society (ACS), 2020.
Abstract: The outbreak of COVID-19 by the end of 2019 has posed serious health threats to humanity and jeopardized the global economy. However, no effective drugs are available to treat COVID-19 currently and there is a great demand to fight against it. Here, we combined computational screening and an efficient cellular pseudotyped virus system, confirming that clinical HDAC inhibitors can efficiently prevent SARS-CoV-2 and potentially be used to fight against COVID-19.